

Amendments to the Claims:

Please cancel claims 1-6, 8-10, and 12; please amend claims 7, 13-14, and 16 as summarized below.

Claim 1. (canceled)

Claim 2. (canceled)

Claim 3. (canceled)

Claim 4. (canceled)

Claim 5. (canceled)

Claim 6. (canceled)

Claim 7. (amended) A FLINT analog resistant to proteolysis at position 218 of SEQ ID NO:1 comprising ~~the protein of~~ <sup>with the exception that the residue at</sup> position 218 <sup>is a</sup> ~~an amino acid substitution in~~ selected from the group <sup>is a</sup> ~~position 218~~ consisting of:

- a. Arg at position 218 is replaced by Gln
- b. Arg at position 218 is replaced by Glu;
- c. ~~Thr at position 216 is replaced by Pro;~~
- d. Arg at position 218 is replaced by Ala;
- e. ~~Arg at position 218 is replaced by Gly;~~
- f. Arg at position 218 is replaced by Ser;
- g. Arg at position 218 is replaced by Val;
- h. Arg at position 218 is replaced by Tyr; and
- i. Arg at position 218 is replaced by Asn; and
- j. ~~Pro at position 217 is replaced by Tyr.~~

Claim 8. (canceled)

Claim 9. (canceled)

Claim 10. (canceled)

Claim 11. (canceled)

Claim 12. (canceled)

Claim 13. (amended) A FLINT analog as in Claim 1 wherein Thr at position 216 of SEQ ID NO:1 is replaced by Pro, and Arg at position 218 is replaced by Gln.

Claim 14. (amended) A method to treat or prevent a disease or condition in a mammal comprising the administration of a therapeutically effective amount of a protease resistant FLINT analog of claim 2 ~~or claim 13~~.

4  
Claim 15. (original) A method as in Claim 14 wherein said disease or condition is acute lung injury, acute respiratory distress syndrome, or ulcerative colitis.

Claim 16. (amended) A pharmaceutical formulation comprising as an active ingredient a protease resistant FLINT analog of claim 2 ~~or claim 13~~ associated with one or more pharmaceutically acceptable carriers, excipients, or diluents thereof.

Claim 17-20 (canceled).

Claim 21. (original) A FLINT analog resistant to proteolysis at position 218 of SEQ ID NO:1 comprising the amino acid sequence of SEQ ID NO:1, wherein Arg at position 218 is substituted by Gln.

Claims 22-23 (canceled)